Informations

1. Oncology Frontier: As the Chairperson of this forum, could you share the topics that you found most compelling during the event? Dr. Yongchang Zhou: Absolutely. This year’s forum was…

Meeting at the Summit，China’s Original Research Takes the International Stage Oncology Frontier: Could you review China’s original research achievements in breast cancer in 2024? Dr. Zefei Jiang: 2024 has been…

The global multicenter, randomized, double-blind phase III RATIONALE-305 trial, led by Professor Ruihua Xu as the Global Leading PI, demonstrated that tislelizumab combined with chemotherapy significantly improves overall survival (OS) compared to placebo plus chemotherapy in patients with advanced gastric cancer. This study offers a new first-line treatment option for patients with advanced gastric cancer.…

Pancreatic cancer, often called the “king of cancers,” remains a formidable disease with poor patient outcomes. Challenges stem from the complexity and invasiveness of surgical procedures and limited progress in systemic therapies, which are still largely chemotherapy-based. However, 2024 brought new developments in pancreatic minimally invasive surgery and innovative treatment strategies. In an interview with…

Innovations in Drug Development ROS1 For patients with ROS1-positive advanced NSCLC, crizotinib was previously the standard treatment. However, its efficacy, particularly in terms of progression-free survival (PFS), was limited to…

Abstract ID: 117TiP Title: Safety and Efficacy of Reduced-Port Laparoscopic Surgery for Colon and Upper Rectal Cancer: A Multicenter, Prospective, Randomized Phase III Study Background Radical resection remains the cornerstone…

Abstract ID: 119TiP Title: A Randomized, Controlled, Multicenter Phase III Study of IBI310 (Anti-CTLA-4 Antibody) Plus Sintilimab (Anti-PD-1 Antibody) as Neoadjuvant Therapy for Resectable MSI-H/dMMR Colon Cancer Presenter: Professor Ruihua…

Key Oncogenic Targets in Focus FGFR2 Approximately 3%–5% of gastric cancer patients exhibit FGFR2 overexpression or amplification, which is associated with tumor dissemination and poor prognosis. Studies on FGFR2 inhibitors…